









Markets
/
Stocks
/
nasdaq-arqt
/

Arcutis Biotherapeutics Inc

ARQT

23.720USD

-0.030-0.13%

Market hours （ET）Quotes delayed by 15 min

2.85BMarket Cap

LossP/E TTM



Arcutis Biotherapeutics Inc

23.720

-0.030-0.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arcutis Biotherapeutics Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arcutis Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

26 / 159

Overall Ranking

69 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

31.000

Target Price

+27.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Arcutis Biotherapeutics Inc Highlights

StrengthsRisks

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 5232.12% year-on-year.

Undervalued

The company’s latest PE is -69.53, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 134.55M shares, decreasing 8.25% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 374.54K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.22, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 99.22M, representing a year-over-year increase of 121.69%, while its net profit experienced a year-over-year increase of 117.84%.

Score

Industry at a Glance

Previous score

8.22

Change



Financials

6.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Arcutis Biotherapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 7.12, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -69.53, which is -99.39% below the recent high of -0.42 and -6.57% above the recent low of -74.09.

Score

Industry at a Glance

Previous score

7.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.25, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Arcutis Biotherapeutics Inc is 30.50, with a high of 34.00 and a low of 29.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

31.000

Target Price

+30.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Arcutis Biotherapeutics Inc

ARQT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 8.83, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 27.35 and the support level at 19.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.98

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Buy

RSI(14)

58.525

Neutral

STOCH(KDJ)(9,3,3)

33.941

Sell

ATR(14)

1.616

High Vlolatility

CCI(14)

29.042

Neutral

Williams %R

44.514

Buy

TRIX(12,20)

1.068

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

24.294

Sell

MA10

24.670

Sell

MA20

22.586

Buy

MA50

19.966

Buy

MA100

17.442

Buy

MA200

15.746

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 109.88%, representing a quarter-over-quarter increase of 0.44%. The largest institutional shareholder is The Vanguard, holding a total of 7.12M shares, representing 5.81% of shares outstanding, with 6.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Jennison Associates LLC

12.25M

+10.30%

Suvretta Capital Management, LLC

11.54M

+0.99%

Rubric Capital Management LP

10.75M

-1.98%

Frazier Life Sciences Management, L.P.

9.87M

+0.00%

BlackRock Institutional Trust Company, N.A.

7.61M

-3.75%

The Vanguard Group, Inc.

Star Investors

7.02M

+3.40%

Polar Capital LLP

5.01M

-25.35%

State Street Investment Management (US)

4.53M

+1.18%

Gilder Gagnon Howe & Co. LLC

4.16M

+1.46%

Morgan Stanley & Co. LLC

3.75M

+21.86%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 6.07, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.73. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.